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KEYWORDS	
	 A	new	series	of	2,6‐diamino‐5‐arylazo‐4‐chloropyrimidine	analogues	(6‐13)	were	synthesizedfrom	 the	 pyrimidine	 scaffold	 5,	 via	 diazotization	 with	 various	 amines.	 Nucleophilic
displacement	 of	 compound	 5	 by	 ethanethiolate	 or	 arylthio	 nucleophiles,	 afforded	 the	 4‐
alkylthio	analogues	(14‐16).	Treatment	of	compound	17	or	18	with	thiourea	under	MWI	gave
the	 4‐thione	 derivatives	 19	 and	 20,	 respectively.	 On	 treatment	 of	 compound	 20	 with	 2‐
mercaptoacetic	acid	furnished	the	4‐thio	analogue	(21).	Reaction	of	compound	19	or	20	with
sodium	hypochlorite	 followed	by	ammonium	hydroxide	afforded	 the	4‐aminothio	analogues
22	 and	 23,	 respectively.	 Oxidation	 of	 compound	 23	 with	 H2O2	 led	 to	 the	 4‐sulphonamide
derivative	24.	All	new	compounds	were	evaluated	 for	 their	 in	vitro	 antiviral	activity	against
the	 replication	of	HIV‐1	and	HIV‐2	 in	MT‐4	cells.	Compounds	14‐16	and	21	 showed	an	EC50
values	of	>	2.12,	1.99,	1.80	and	1.92	μg/mL,	respectively.	 In	addition,	preliminary	structure‐
activity	relationship	and	molecular	modeling	of	compound	15	has	been	studied.	
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1.	Introduction	
	
Pyrimidine	 and	 its	 derivatives	 demonstrated	 a	 diverse	
array	 of	 biological	 and	 pharmacological	 activities	 including	
antitumor	 [1‐6],	 antimicrobial	 [7‐10],	 and	 antihypertensive	
[11]	 in	 addition	 to	 their	 cardiovascular	 [12,13]	 and	 diuretic	
[14,15]	 properties.	 Some	 pyrimidine	 analogues	 exhibited	
potent	 antiviral	 activity	 against	 a	wide	 spectrum	of	 unrelated	
viruses,	such	as	poliovirus	[16]	and	herpes	virus	[17]	and	anti‐
HIV	 agents	 [18‐20],	 whereas	 two	 recent	 diarylpyrimidines	
(DAPY),	 rilpivirine	1	 [21]	and	etravirine	2	 [22,	23]	have	been	
classified	 as	 non‐nucleoside	 reverse	 transcriptase	 inhibitors	
(NNRTI's),	 meanwhile	 Chen	 et	 al.	 [24]	 have	 reported	 a	 new	
class	 of	 diarylpyrimidines	 (CHX‐DAPYs)	 as	 potent	 NNRTI's.	
Further,	 several	 pyrimidine	 derivatives	 exhibited	 significant	
antitumor	 activity	 e.g.	 imatinib	mesylate	 (Gleevec,	3)	 [25],	 an	
interesting	novel	agent	 for	 the	 treatment	of	chronic	Leukemia	
is	 the	 tyrosine	 kinase	 inhibitor	 which	 contains	 a	 4‐pyridyl‐
substituted	 pyrimidine‐2‐amine,	 in	 addition	 to	 a	 2,4‐diamino‐
N4‐6‐diaryl‐pyrimidines	 where	 the	 latter	 were	 identified	 to	
block	 the	 proliferation	 of	 tumor	 cell	 lines	 in	 vivo,	 especially	
duodenum	 cancer	 [26].	Monastrol	4	 [27]	 is	 another	model	 of	
pyrimidine	derivative	 as	 inhibitor	of	 kinesin	Eg5	 that	 interact	
with	microtubuline	and	then	causes	mitotic	arrest	[28]	(Figure	
1).	
	
Recently,	 Kim	 et	 al.	 [29]	 have	 reported	 some	 novel	
pyrimidine	derivatives	as	potent	acid	pump	antagonists	(APAs).	
Jian	 et	 al.	 [30]	 have	 reviewed	 the	 biological	 and	 medicinal	
significance	of	pyrimidines	extensively.	
	
 	
Figure	1.	Pyrimidine	analogues	antitumor	and	anti‐HIV	drugs.	
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Scheme	1	
	
	
In	 continuation	 of	 our	 ongoing	 work	 on	 the	 synthesis	 of	
new	 anti‐HIV	 pyrimidine	 derivatives	 [31,32],	 we	 report	 here	
the	synthesis	of	new	of	series	of	pyrimidines	having	substituted	
amino	and	thio	groups	with	evaluation	of	their	anti‐HIV	activity	
as	well	the	SAR	and	molecular	modeling	study.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
Melting	 points	 are	 uncorrected	 and	 were	 measured	 on	 a	
Büchi	melting	point	apparatus	B‐545	 (Büchi	Labortechnik	AG,	
Switzerland).	 NMR	 data	 were	 obtained	 on	 400	 and	 600	MHz	
(1H)	and	150.91	MHz	 (13C)	 spectrometers	 (Avance	 III,	Bruker,	
Germany)	with	TMS	as	internal	standard	and	on	the	δ	scale	in	
ppm.	Heteronuclear	assignments	were	verified	by	1H,	13C	HMBC	
and	1H,	13C	HSQC	NMR	experiments.	Microanalytical	data	were	
obtained	with	 a	 Vario,	 Elemental	 analyzer	 (Shimadzu,	 Japan).	
Analytical	 silica	 gel	 TLC	 plates	 60F254	 were	 purchased	 from	
Merck.	 Microwave	 supported	 reaction	 was	 performed	 in	 a	
SmithSynthesizer	(temperature	control	of	irradiation	power	up	
to	 800	 W).	 All	 reagents	 were	 obtained	 from	 commercial	
suppliers	and	were	used	without	further	purification.		
	
2.2.	Synthesis	
	
2.2.1.	General	procedure	for	the	preparation	of	2,6‐diamino‐
4‐alkylamino‐5‐((p‐bromophenyl)diazenyl)pyrimidine	
derivatives	(6‐13)	
	
A	solution	of	compound	5	(164	mg,	0.50	mmol)	in	DMF	(20	
mL)	and	an	appropriate	 amine	 (1.00	mmol)	was	heated	 in	 an	
oil	bath	at	90‐100	°C	for	4‐5	h.	Then	water	(25	mL)	was	added,	
the	 solution	 was	 cooled,	 and	 the	 yellow	 precipitate	 was	
collected,	washed	with	water,	and	dried.	Recrystallization	from	
ethanol	afforded	the	desired	product	(Scheme	1).	
2,6‐Diamino‐4‐benzylamino‐5‐p‐bromophenylazopyrimidine	
(6):	 From	 benzylamine	 (107	mg).	 Yield:	 110	mg	 (55%).	M.p.:	
160‐167	 °C.	Rf	 =	 0.75.	 1H	 NMR	 (400	MHz,	 DMSO‐d6,	 δ,	 ppm):	
8.84‐8.14	(br.	s.,	2H,	NH2),	7.72	(d,	2H,	J	=	7.9	Hz,	H‐Ar),	7.54	(d,	
2H,	J	=	7.9	Hz,	H‐Ar),	7.36‐7.24	(m,	6H,	H‐Ar	+	CH2NH),	6.62	(br	
s.,	2H,	NH2),	4.72	(d,	2H,	J	=	6.5	Hz,	CH2).	13C	NMR	(150.91	MHz,	
DMSO‐d6,	δ,	ppm):	163.3	(C(2)pyrimid.),	161.0	(C(4)pyrimid.),	152.0	
(C(6)pyrimid.),	139.0,	131.7,	128.3,	127.3,	126.9	(Carom.),	122.7	(C‐
Br),	119.1	(Carom.),	110.1	(C(5)pyrimid.);	42.9	(CH2).	Anal.	calcd.	for	
C17H16BrN7:	C,	51.27;	H,	4.05;	N,	24.62.	Found:	C,	51.04;	H,	3.92;	
N	24.41	%.	
2,6‐Diamino‐5‐((p‐bromophenyl)diazenyl)‐4‐(2‐picolyl	
amino)pyrimidine	(7):	From	2‐picolylamine	(108	mg).		Yield:	64	
mg	 (32%).	 M.p.:	 193‐196	 °C.	 Rf	 =	 0.54.	 1H	 NMR	 (400	 MHz,	
DMSO‐d6,	δ,	ppm):	8.50	(d,	2H,	J	=	4.8	Hz,	NH2),	8.36	(d,	1H,	J	=	
8.2	Hz,	Hpicolyl‐6'')‐Ar),	7.78	(m,	3H,	Harom.‐3'	+	Harom.‐5'	+	Hpicolyl‐
4''),	7.55	(d,	2H,	J	=	8.2	Hz,	Hpicolyl‐3''	+	Hpicolyl‐5''),	7.31	(d,	2H,	J	=	
8.0	Hz,	Harom.‐2'	 +	Harom.‐6'),	 6.60	 (br	 s.,	 2H,	NH2),	 4.73	 (d,	 2H,	
JNH,CH2	=	6.1	Hz,	HNCH2),	3.28	(d,	1H,	HNCH2).	13C	NMR	(150.91,	
DMSO‐d6,	δ,	ppm):	163.2	(C(2)pyrimid.),	161.5	(C(4)pyrimid.),	157.6	
(C(2')picolyl),	 152.0	 (C(6)pyrimid.),	 149.5	 (C(6')picolyl),	 141.6	
(C(4')picolyl),	 131.7,	 122.9,	 122.1	 (Carom.),	 119.3	 (C(3')picolyl	 +	
C(5')picolyl),	 110.1	 (C(5)pyrimid.),	 40.0	 (NCH2).	 Anal.	 calcd.	 for	
C16H15BrN8:	C,	48.13;	H,	3.79;	N,	28.07.	Found:	C,	47.91;	H,	3.68;	
N,	27.81	%.	
2,6‐Diamino‐5‐((p‐bromophenyl)diazenyl)‐4‐dimethylamino	
pyrimidine	 (8):	 From	 dimethylamine	 (45	 mg).	 Yield:	 124	 mg	
(74%).	M.p.:	 204‐207	 °C	 (Dec.).	Rf	 =	 0.55.	 1H	NMR	 (400	MHz,	
DMSO‐d6,	δ,	ppm):	7.79	(br	s.,	2H,	NH2),	7.61	(d,	2H,	J	=	7.9	Hz,	
H‐Ar),	7.54	(d,	2H,	J	=	7.9	Hz,	H‐Ar),	6.81	(br	s.,	2H,	NH2),	3.31	
(s,	6H,	NMe2).	 13C	NMR	(DMSO‐d6,	δ,	 ppm):	163.0	 (C(2)pyrimid.),	
161.5	 (C(4)pyrimid.),	 156.0	 (C(6)pyrimid.),	 132.5,	 130.2,	 126.5	
(Carom.),	 122.9	 (C‐Br),	 104.1	 (C(5)pyrimid.),	 39.1	 (NMe2).	 Anal.	
calcd.	 for	 C12H14BrN7:	 C,	 42.87;	 H,	 4.20;	 N,	 29.16.	 Found:	 C,	
42.66;	H,	4.08;	N,	28.98	%.	
2,6‐Diamino‐5‐((p‐bromophenyl)diazenyl)‐4‐diethylamino	
pyrimidine	 (9):	 From	 diethylamine	 (73	 mg).	 Yield:	 126	 mg	
(69%).	 M.p.:	 145‐147	 °C	 (Dec).	Rf	 =	 0.66.	 1H	 NMR	 (400	MHz,	
DMSO‐d6,	δ,	ppm):	9.14	(br	s.,	2H,	NH2),	7.72	(d,	2H,	J	=	7.9	Hz,	
H‐Ar),	7.68	(d,	2H,	J	=	7.9	Hz,	H‐Ar),	6.60	(br	s.,	2H,	NH2),	3.99	
(q,	4H,	 J	=	7.1	Hz,	2xCH2CH3),	1.23	(t,	6H,	2xCH2CH3).	 13C	NMR	
(150.91,	 DMSO‐d6,	 δ,	 ppm):	 163.0	 (C(2)pyrimid.),	 162.0	
(C(4)pyrimid.),	 157.2	 (C(6)pyrimid.),	 132.1,	 130.6,	 127.9	 (Carom.),	
121.6	 (C‐Br),	 100.0	 (C(5)pyrimid.),	 41.6	 (2xCH2CH3),	 11.4	
(2xCH2CH3).	 Anal.	 calcd.	 for	 C14H18BrN7:	 C,	 46.16;	 H,	 4.98;	 N,	
29.92.	Found:	C,	45.89;	H,	4.88;	N,	28.68	%.	
2,6‐Diamino‐5‐((p‐bromophenyl)diazenyl)‐4‐diphenylamino	
pyrimidine	 (10):	 From	diphenylamine	 (169	mg).	 Yield:	 83	mg	
(36%).	 M.p.:	 155‐158	 °C	 (Dec).	Rf	 =	 0.58.	 1H	 NMR	 (400	MHz,	
DMSO‐d6,	δ,	ppm):	8.19	(br	s.,	2H,	NH2),	7.64‐7.08	(m,	14H,	H‐
Ar),	6.81	(br	s.,	2H,	NH2).	13C	NMR	(150.91,	DMSO‐d6,	δ,	ppm):	
163.1	(C(2)pyrimid.),	161.3	(C(4)pyrimid.),	156.0	(C(6)pyrimid.),	140.8,	
138.8,	 132.6,	 130.2,	 129.6,	 129.2,	 127.3	 (Carom.),	 123.2	 (C‐Br),	
104.8	(C(5)pyrimid.).	Anal.	calcd.	for	C22H18BrN7:	C,	57.40;H,	3.94;	
N,	21.30.	Found:	C,	57.18;	H,	3.82;	N,	21.06	%.	
2,6‐Diamino‐4‐piperidino‐5‐p‐bromophenylazo‐pyrimidine	
(11):	From	piperidine	(85	mg).	Yield:	167	mg	(89%).	M.p.:	190‐
197	°C.	Rf	=	0.90.	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	7.96	(br	
s.,	2H,	NH2),	7.78	(d,	2H,	J	=	8.0	Hz,	Harom.‐3'	+	Harom.‐5'),	7.56	(d,	
2H,	J	=	8.0	Hz,	Harom.‐2'	+	Harom.‐6'),	6.69	(br	s.,	2H,	NH2),	3.71	(m,	
4H,	 2xCH2(piperidin)),	 1.65‐1.50	 (m,	 6H,	 3xCH2(piperidin)).	 13C	 NMR	
(150.91,	 DMSO‐d6,	 δ,	 ppm):	 162.7	 (C(2)pyramid.),	 160.8	
(C(4)pyrimid.),	 157.0	 (C(6)pyrimid.),	 132.7,	 130.1,	 128.6	 (Carom.),	
123.3	(C‐Br),	106.9	(C(5)pyrimid.),	53.0	(2xCH2(piperidin)),	25.9,	24.4	
(3xCH2(piperidin)).	Anal.	calcd.	for	C15H18BrN7:	C,	47.88;	H,	4.82;	N,	
26.06.	Found:	C,	47.59;	H,	4.68;	N,	25.89	%.	
2,6‐Diamino‐5‐((p‐bromophenyl)diazenyl)‐4‐morpholino‐
pyrimidine	 (12):	 From	 morpholine	 (87	 mg).	 Yield:	 166	 mg	
(88%).	M.p.:	238‐242	°C.	Rf	=	0.58.	1H	NMR	(400	MHz,	DMSO‐d6,	
δ,	ppm):	7.79	(br	s.,	2H,	NH2),	7.62	(d,	2H,	J	=	7.9	Hz,	Harom.‐3'	+		
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Harom.‐5'),	7.53	(d,	2H,	J	=	7.9	Hz,	Harom.‐2'	+	Harom.‐6'),	6.84	(br	s.,	
2H,	 NH2),	 3.88	 (m,	 4H	 2xCH2(morpholin),	 3.71	 (m,	 4H,	
2xCH2(morpholin).	 13C	 NMR	 (150.91,	 DMSO‐d6,	 δ,	 ppm):	 163.3	
(C(2)pyrimid.),	161.3	(C(4)pyrimid.),	156.8	(C(6)pyrimid.),	132.6,	130.6,	
127.5	 (Carom.),	 122.9	 (C‐Br),	 105.8	 (C(5)pyrimid.),	 66.9	
(2xCmorpholin),	49.6	(2xCmorpholin).	Anal.	calcd.	for	C14H16BrN7O:	C,	
44.46;	H,	4.26;	N,	25.92.	Found:	C,	44.19;	H,	4.08;	N,	25.69	%.	
2,6‐Diamino‐5‐((p‐bromophenyl)diazenyl)‐4‐piperazino‐
pyrimidine	 (13):	 From	 piperazine	 (86	 mg).	 Yield:	 153	 mg	
(81%).	M.p.:	238‐242	°C.	Rf	=	0.11.	1H	NMR	(400	MHz,	DMSO‐d6,	
δ,	ppm):	8.07	(br	s.,	2H,	NH2),	7.62	(d,	2H,	J	=	7.7	Hz,	Harom.‐3'	+	
Harom.‐5'),	7.52	(d,	2H,	J	=	7.7	Hz,	Harom.‐2'	+	Harom.‐6'),	6.66	(br	s.,	
2H,	 NH2),	 3.30	 (br	 s.,	 1H,	 NH),	 3.09	 (br	 s.,	 4H,	 2xCH2(piperazin),	
2.89	 (br	 s.,	 4H,	 2xCH2(piperazin).	 13C	 NMR	 (150.91,	 DMSO‐d6,	 δ,	
ppm):	163.7	(C(2)pyrimid.),	162.2	(C(4)pyrimid.),	157.1	(C(6)pyrimid.),	
132.7,	 130.4,	 127.4,	 (Carom.),	 122.9	 (C‐Br),	 105.8	 (C(5)pyrimid.),	
49.6,	47.2	(4xCpiperazin).	Anal.	calcd.	 for	C14H17BrN8:	C,	44.57;	H,	
4.54;	N,	29.70.	Found:	C,	44.27;	H,	4.40;	N,	27.75	%.	
	
2.2.2.	General	procedure	for	the	preparation	of	2,6‐diamino‐
4‐alkyl‐	and	arylthio‐5‐((p‐bromophenyl)diazenyl)	
pyrimidine	derivatives	(14‐16)	
	
A	solution	of	compound	5	(100	mg,	0.31	mmol)	in	DMF	(20	
mL)	 and	 sodium	 ethanethiolate,	 sodium	 thiophenolate	 or	 p‐
chlorobenzenethiol	 (0.90	mmol)	was	 heated	 in	 an	 oil	 bath	 at	
90‐100	°C	for	4‐6	h.	After	cooling,	the	solution	was	evaporated	
and	the	residue	was	co‐evaporated	with	toluene	(4×15	mL)	to	
give	 a	 crude	 solid.	 Recrystallization	 from	 ethanol	 or	
ethanol:ether	 (1:3,	 v:v)	 afforded	 the	 desired	 product	 (Scheme	
2).	
5‐((4‐Bromophenyl)diazenyl)‐6‐(ethylthio)pyrimidine‐2,4‐
diamine	 (14):	 From	 sodium	 ethanethiolate	 (76	mg).	 Yield:	 81	
mg	 (74%).	 M.p.:	 236‐238	 °C.	 Rf	 =	 0.63.	 1H	 NMR	 (400	 MHz,	
DMSO‐d6,	δ,	ppm):	9.26	 (br	 s.,	2H,	NH2	 ),	8.19	(br	s.,	2H,	NH2),	
7.72	(d,	2H,	J	=	7.9	Hz,	Harom.‐3'	+	Harom.‐5'),	7.69	(d,	2H,	J	=	7.9	
Hz,	Harom.‐2'	+	Harom.‐6'),	3.99	(q,	2H,	J	=	7.1	Hz,	CH2CH3),	1.23	(t,	
3H,	 CH2CH3).	 13C	 NMR	 (150.91,	 DMSO‐d6,	 δ,	 ppm):	 163.0	
(C(4)pyrimid.),	162.0	(C(2)pyrimid.),	157.2	(C(6)pyrimid.),	132.1,	130.6,	
127.9	(Carom.),	121.6	(C‐Br),	100.0	(C(5)pyrimid.),	41.6	(SCH2CH3),	
11.4	(SCH2CH3).	MS	((+)‐FAB):	m/z	=	352/354	[M]+.	Anal.	calcd.	
for	C12H13BrN6S:	C,	40.80;	H,	3.71;	N,	23.79.	Found:	C,	40.61;	H,	
3.60;	N,	23.54	%.	
2,4‐Diamino‐5‐((p‐bromophenyl)diazenyl)‐6‐(phenylthio)	
pyrimidine	(15):	From	sodium	benzenethiolate	(117	mg).	Yield:	
85	mg	(68%).	M.p.:	224‐226	°C	(Dec.).	Rf	=	0.53.	1H	NMR	(400	
MHz,	DMSO‐d6,	 δ,	 ppm):	 8.32	 (br	 s.,	 2H,	NH2),	 8.19	 (br	 s.,	 2H,	
NH2),	 7.90‐7.59	 (m,	 9H,	Harom.).	 13C	NMR	 (150.91,	DMSO‐d6,	 δ,	
ppm):	181.4	(C(4)pyrimid.),	164.6	(C(2)pyrmid.),	156.0	(C(6)pyrimid.),	
133.5,	 132.2,	 132.1,	 129.0,	 127.8,	 123.8	 (Carom.),	 122.1	 (C‐Br),	
118.1	 (C(5)pyrimid.).	 MS	 ((+)‐FAB):	m/z	 =	 401/402	 [M]+.	 Anal.	
calcd.	 for	 C16H13BrN6S:	 C,	 47.89;	 H,	 3.27;	 N,	 20.94.	 Found:	 C,	
47.77;	H,	3.16;	N,	20.76	%.	
	
	
2,4‐Diamino‐5‐((p‐bromophenyl)diazenyl)‐6‐((4‐chloro	
benzyl)thio)pyrimidine	 (16):	 From	 4‐chlorobenzylthiol	 (143	
mg).	Yield:	74	mg	(53%).	M.p.:	232‐236	°C	(Dec.).	Rf	=	0.55.	1H	
NMR	 (400	MHz,	DMSO‐d6,	 δ,	 ppm):	9.26	 (br	 s.,	2H,	NH2),	 8.19	
(br	s.,	2H,	NH2),	7.75‐7.29	(m,	8H,	Harom.),	4.36	(s,	2H,	CH2).	13C	
NMR	 (150.91,	 DMSO‐d6,	 δ,	 ppm):	 164.6	 (C(4)pyrimid.),	 161.1	
(C(2)pyrmid.),	155.9	(C(6)pyrimid.),	132.2,	132.0,	131.1,	128.4,	123.2	
(Carom.),	 122.1	 (C‐Br),	 118.6	 (C(5)pyrimid.),	 31.2	 (CH2).	 MS	 ((+)‐
FAB):	m/z	 =	 448/450	 [M]+.	 Anal.	 calcd.	 for	 C17H14BrClN6S:	 C,	
45.40;	H,	3.14;	N,	18.69.	Found:	C,	45.21;	H,	3.02;	N,	18.42	%.	
	
2.2.3.	Reaction	of	compound	17	and	18	with	thiourea	under	
MWI	
	
A	crushed	mixture	of	compound	17	(100	mg,	0.46	mmol)	or	
18	(100	mg,	0.71	mmol)	and	thiourea	(10	mg,	1.31	mmol)	was	
irradiated	 in	 a	 microwave	 oven	 (800	 W)	 for	 25	 min.	 The	
mixture	was	poured	 into	 ice‐cold	water	 and	 the	 solid	 residue	
was	 washed	 with	 ether	 followed	 by	 a	 little	 amount	 of	 cold	
ethanol.	 Recrystallization	 from	 ethanol	 afforded	 the	 desired	
product	(Scheme	3).	
2‐Amino‐6‐(benzyloxy)pyrimidine‐4‐thione	 (19):	 Yield:	 76	
mg	 (71%).	 M.p.:	 136‐138	 °C.	 Rf	 =	 0.57.	 1H	 NMR	 (400	 MHz,	
DMSO‐d6,	 δ,	 ppm):	 7.42‐7.33	 (m,	 5H,	 Harom.),	 7.07	 (br	 s.,	 2H,	
NH2),	6.15	(s,	1H,	NH),	5.31	(s,	1H,	Hpyrimid.‐5),	5.13	(s,	2H,	CH2).	
13C	 NMR	 (150.91,	 DMSO‐d6,	 δ,	 ppm):	 184.3	 (C6=S),	 170.3	
(C(4)pyrimid.),	154.7	 (C(2)pyrimid.),	137.1	 (C(1')arom.),	128.9,	128.8,	
128.4,	 128.2	 (Carom.),	 94.7	 (C(5)pyrimid.),	 65.7	 (CH2).	 Anal.	 calcd.	
for	C11H11N3OS:	C,	56.63;	H,	4.75;	N,	18.01.	Found:	C,	56.41;	H,	
4.65;	N,	17.82	%.	
2‐Amino‐6‐methoxypyrimidine‐4‐thione	 (20):	 Yield:	 76	 mg	
(67%).	M.p.:	 289‐292	 °C	 (Dec.).	Rf	 =	 0.37.	 1H	NMR	 (400	MHz,	
DMSO‐d6,	δ,	ppm):	7.28	(br	s.,	2H,	NH2),	6.76	(s,	1H,	NH),	5.35	
(s,	1H,	Hpyrimid.‐5),	4.07	(s,	3H,	OCH3).	 13C	NMR	(150.91,	DMSO‐
d6,	 δ,	 ppm):	 184.9	 (C=S),	 171.8	 (C(4)pyrimid.),	 153.8	 (C2)pyrimid.),	
94.1	 (C(5)pyrimid.),	 57.0	 (OMe).	 Anal.	 calcd.	 for	 C5H7N3OS:	 C,	
38.20;	H,	4.49;	N,	26.73.	Found:	C,	8.43;	H,	4.37;	N,	26.52	%.	
	
2.2.4.	Synthesis	of	2‐(2‐amino‐6‐methoxypyrimidin‐4‐yl)	
mercapto	acetic	acid	(21)	
	
To	a	solution	of	compound	20	(55	mg,	0.34	mmol)	in	DMF	
(5	mL)	containing	potassium	carbonate	(30	mg)	was	added	2‐
mercaptoacetic	 acid	 (30	mg,	 0.32	mmol)	 and	 stirred	 at	 room	
temperature	 for	 16	 h.	 After	 cooling,	 the	mixture	 was	 filtered	
and	 the	 filtrated	 was	 evaporated	 to	 dryness	 and	 the	 residue	
was	 purified	 on	 a	 short	 column	 of	 SiO2	 (5	 g).	 Elution	 with	
chloroform:methanol	(95:5,	v:v)	afforded	compound	21	(35	mg,	
47%)	 (Scheme	 3).	 M.p.:	 142‐154	 °C	 (Dec.).	 Rf	 =	 0.1.	 1H	 NMR	
(400	MHz,	DMSO‐d6,	δ,	ppm):	10.95	(s,	1H,	OH),	7.23	(br	s.,	2H,	
NH2),	 6.33	 (s,	 1H,	 Hpyrimid.‐5),	 4.08	 (s,	 2H,	 CH2),	 3.88	 (s,	 3H,	
OMe).	 13C	NMR	(150.91,	DMSO‐d6,	δ,	ppm):	71.7	(CO2H),	170.6	
(C(6)pyrimid.),	 168.5	 (C4)pyrimid.),	 155.9	 (C(2)pyrimid.),	 94.6	
(C(5)pyrimid.),	51.9	(OMe),	31.0	(CH2).		
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Scheme	3	
	
	
Anal.	calcd.	for	C7H9N3O3S:	C,	39.06;	H,	4.21;	N,	19.52.	Found:	C,	
38.82;	H,	4.10;	N,	19.32.	
	
2.2.5.	Reaction	of	compound	21	with	sodium	hypochlorite	
and	ammonium	hydroxide	
	
Compound	 21	 (104	 mg,	 0.66	 mmol)	 or	 20	 (54	 mg,	 0.34	
mmol)	was	added	to	a	solution	of	sodium	hypochlorite	(5	mL)	
and	 the	 reaction	 mixture	 was	 stirred	 at	 60	 °C	 for	 4	 h.	
Ammonium	 hydroxide	 (10	 mL)	 was	 added	 to	 the	 reaction	
mixture,	and	stirred	for	an	additional	1	h	at	room	temperature,	
the	 precipitate	 was	 filtered	 and	 washed	 with	 water	 several	
times	 and	 dried,	 followed	 by	 washing	 with	 dry	 ether	 to	 give	
compound	22	or	23,	respectively	(Scheme	3).	
2‐Amino‐4‐(aminothio)‐6‐(benzyloxy)pyrimidine	(22):	Yield:	
111	mg	(68%).	M.p.:	286‐289	°C.	Rf	=	0.32.	1H	NMR	(400	MHz,	
DMSO‐d6,	 δ,	 ppm):	 7.43‐7.33	 (m,	 5H,	 Harom.),	 7.33	 (br	 s.,	 2H,	
NH2),	6.14	(s,	1H,	Hpyrimid.‐5),	5.39	(br	s.,	2H,	SNH2),	5.31	(s,	2H,	
CH2).	13C	NMR	(150.91,	DMSO‐d6,	δ,	ppm):	189.4	(CSNH2),	166.1	
(C(4)pyrimid.),	 160.5	 (C2)pyrimid.),	 129.0‐126.9	 (Carom.),	 100	
(C(5)pyrimid.).	 Anal.	 calcd.	 for	 C11H12N4OS:	 C,	 53.21;	 H,	 4.87;	 N,	
22.56.	Found:	C,	52.98;	H,	4.70;	N,	22.68	%.	
2‐Amino‐4‐(aminothio)‐6‐methoxypyrimidine	(23):	Yield:	36	
mg	 (61%).	 M.p.:	 288‐291	 °C.	 Rf	 =	 0.43.	 1H	 NMR	 (400	 MHz,	
DMSO‐d6,	δ,	ppm):	7.41	(br	s.,	2H,	NH2),	5.99	(s,	1H,	Hpyrimid.‐5),	
3.87	(s,	3H,	OMe),	2.31	(s,	2H,	SNH2).	13C	NMR	(150.91,	DMSO‐
d6,	 δ,	 ppm):	 189.0	 (C(6)pyrimid.),	 167.8	 (C4)pyrimid.),	 153.2	
(C(2)pyrimid.),	 94.9	 (C(5pyrimid.),	 57.0	 (OMe).	 Anal.	 calcd.	 for	
C5H8N4OS:	C,	34.87;	H,	4.68;	N,	32.53.	Found:	C,	34.59;	H,	4.55;	
N,	32.33	%.	
	
2.2.6.	Synthesis	of	2‐amino‐6‐methoxypyrimidine‐4‐
sulfonamide	(24)	
	
A	suspension	of	compound	23	(80	mg,	0.46	mmol)	in	H2O2	
(5	mL)	was	stirred	at	 room	temperature	 for	4	h.	The	solution	
was	 evaporated	 to	 dryness	 and	 the	 residue	was	washed	with	
water	 (3	 x	10	mL),	dried	and	 then	 then	with	ether.	The	dried	
crude	product	was	purified	on	a	short	SiO2	column	(5	g)	using	
chloroform:methanol	(4:1,	v:v)	as	eluent,	to	give	compound	24	
(70	mg,	74%)	(Scheme	3).	M.p.:	156‐158	°C.	1H	NMR	(400	MHz,	
DMSO‐d6,	δ,	ppm):	7.32	(br	s.,	2H,	NH2),	6.51	(s,	1H,	Hpyrimid.‐5),	
3.98	 (s,	 3H,	OMe),	 2.11	 (br	 s.,	 2H,	 SO2NH2).	 13C	NMR	 (150.91,	
DMSO‐d6,	 δ,	 ppm):	 168.9	 (C(6)pyrimid.),	 165.1	 (C4)pyrimid.),	 154.7	
(C(2)pyrimid.),	 96.2	 (C(5)pyrimid.),	 57.2	 (OMe).	 Anal.	 calcd.	 for	
C5H8N4O3S:	C,	29.41;	H,	3.95;	N,	27.44.	Found:	C,	29.19;	H,	3.86;	
N,	27.21	%.	
	
3.	Results	and	discussion	
	
3.1.	Chemistry	
	
Recently,	 reported	 the	 synthesis	 of	 azopyrimidine	5	 [33],	
and	selected	here	as	a	starting	material	for	the	synthesis	of	new	
azopyrimidine	analogues	having	alkyl	and	aryl	amino	groups	at	
C‐4.	 Thus,	 compound	 5	 was	 subjected	 to	 a	 nucleophilic	
displacement	 of	 chlorine	 group	 by	 treatment	 with	 various	
amines	 in	 DMF	 at	 90‐100	 °C	 for	 4‐5	 h,	 leading	 to	 the	 new	
derivatives	6‐13	in	good	to	moderate	yields	(55‐89	%),	except	
the	products	7	and	10	were	obtained	in	a	lower	yields	32	and	
36%,	 respectively	 (Scheme	 1),	 might	 due	 to	 the	 steric	 factor	
(Scheme	1).	
The	structures	of	6‐13	were	established	by	1H,	13C	NMR	and	
mass	spectral	data.	 In	the	1H	NMR	spectra,	both	amino	groups	
at	C‐2	and	C‐6	of	pyrimidine	backbone	appeared	almost	at	the	
same	regions	as	broad	singlets	at	δ	6.84‐6.38	ppm	and	δ	10.61‐
7.79	ppm,	 respectively,	 assigned	by	D2O	exchange.	The	amino	
groups	at	C‐6	of	 the	analogue	6	showed	two	broad	singlets	 (δ	
8.85	and	8.14	ppm)	and	not	doublets	as	expected,	might	be	due	
to	the	hydrogen	bonding	with	the	nitrogen	of	the	azo	group	at	
C‐5.	The	aromatic	and	the	aliphatic	protons	were	fully	analyzed	
(c.f.	Experimental	section).	In	the	13C	NMR	spectra	of	6‐13,	C‐2	
and	 C‐4	 of	 the	 pyrimidine	 scaffold	 resonated	 at	 the	 region	 δ	
164.0‐163.2	 ppm	 and	 the	 region	 δ	 162.3‐160.0	 ppm,	
respectively.	C‐5	and	C‐6	appeared	at	the	regions	δ	110.1‐100.0	
and	157.7‐152.0	ppm,	respectively.	The	aromatic	carbon	atoms	
C‐4'	 carrying	 bromine	 residue	 were	 resonated	 the	 regions	 δ	
123.8‐118.9	ppm,	while	 the	aromatic	carbon	atoms	C‐1'	 ‐	C‐6'	
of	 the	 pyrimidine	 analogues	 6‐13	 were	 resonated	 at	 the	
regions	 δ	140.8‐122.6	 ppm.	 The	 aliphatic	 carbon	 atoms	were	
fully	analyzed	(cf	Experimental	section).		
Next,	 the	 analogue	 5	 was	 used	 as	 a	 precursor	 for	 the	
synthesis	 of	 new	 5‐arylazo‐4‐ethyl(aryl)thio‐pyrimidine	 deri‐
vatives	to	examine	their	antiviral	activity	in	comparison	to	the	
azoaryl	 analogues	6‐13.	 Thus,	 treatment	 of	 compound	5	with	
sodium	 ethanethiolate,	 sodium	 thiophenolate,	 or	 p‐chloro‐
benzylthiol	 in	DMF	afforded,	via	nucleophilic	displacements	of	
the	chlorine	group,	14‐16	in	74,	68	and	53%	yield,	respectively	
(Scheme	2).	
The	structures	of	compounds	14‐16	were	assigned	by	 the	
1H	 and	 13C	 NMR	 spectra.	 The	 1H	 NMR	 spectra	 showed	 rather	
similar	 patterns	 for	 the	 phenyl	 and	 ethyl	 protons.	 The	
methylene	 and	 methyl	 protons	 of	 SEt	 group	 appeared	 as	
quartet	 and	 triplet	 at	 δ	 3.99	 and	 1.36	 ppm	 (J	 =	 7.1	 Hz),	
respectively,	whereas	the	aromatic	protons	were	fully	analysed	
(cf	Experimental	section).	
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Figure	2.	JC,H	Correlations	in	the	HMBC	NMR	spectrum	of	compound	14.
	
	
In	 the	 13C	NMR	spectra	of	compounds	14‐16,	C‐4,	C‐5	and	
C‐6	 together	with	 the	 aromatic	 carbon	 atoms	were	 identified.	
However,	 compound	 14	 has	 been	 selected	 for	 further	 NMR	
experiment.	 In	 the	 gradient‐selected	 HMBC	 spectrum	 [34]	 of	
compound	 14,	 C‐4	 of	 the	 pyrimidine	 ring	 at	 δ	 163.0	 ppm	
showed	 a	 2JC,H	 coupling	 with	 methylene	 protons	 of	 CH3CH2S	
group	 at	 δ	 3.99	 ppm,	 in	 addition	 to	 a	 3JC,H	 coupling	 with	 the	
methyl	 protons	 of	 the	CH3CH2S	 group	 at	δ	 1.23	ppm.	 Further,	
the	aromatic	protons	H‐3'	and	H‐5'	at	δ	7.72	ppm	revealed	two	
2JC,H	 coupling	with	 C‐4'	 (C‐Br)	 of	 the	 aromatic	 ring	 at	 δ	 121.6	
ppm,	 while	 the	 same	 carbon	 atom	 (C‐Br)	 showed	 two	 3JC,H	
couplings	with	H‐2'	 and	H‐6'	 of	 the	 same	 ring	 at	 δ	 7.68	 ppm	
(Figure	2).	
Our	work	was	modified	by	conversion	of	the	chloro	residue	
in	the	pyrimidine	scaffold	to	the	thione,	following	Lawson	and	
Tankler	method	[35].	Thus,	compound	17	and	18	were	treated	
with	 thiourea	 under	 microwave	 irradiation	 (MWI)	 in	 a	 free	
solvent	 condition	 for	 15	 min	 afforded,	 after	 purification,	 the	
pyrimidine‐thione	analogues	19	and	20	 in	71	and	67	%	yield,	
respectively.	 Treatment	 of	 compound	 20	 with	 2‐mercapto	
acetic	 acid	 in	 DMF	 in	 the	 presence	 of	 K2CO3	 at	 room	
temperature	 for	 16	 h	 afforded	 regioselectively	 [36],	 after	
chromatographic	purification,	4‐thio‐ethylacetic	acid	derivative	
21	(47	%).	
Next,	 treatment	 of	 compound	 19	 and	 20	 with	 sodium	
hypochlorite	followed	by	ammonium	hydroxide,	following	Rice	
et	 al.	 method	 [37],	 furnished	 after	 purification,	 the	 4‐
aminothio‐pyrimidine	 derivatives	 22	 and	 23	 in	 61	 and	 68%	
yield,	 respectively.	 Oxidation	 of	 compound	 23	 with	 H2O2	 at	
room	 temperature	 afforded,	 after	 chromatographic	 purify‐
cation,	the	sulfonamide	24	in	74%	yield	(Scheme	3).	
The	 structures	 of	 compound	19‐24	 were	 elucidated	 from	
their	 1H	 and	 13C	 NMR	 spectra.	 In	 the	 1H	 NMR	 spectra	 of	
compounds	 19	 and	 20,	 H‐5	 of	 the	 pyrimidine	 ring	 were	
appeared	 at	 δ	 5.31	 and	 5.39	 ppm,	 respectively,	 whereas	 the	
protons	 of	 the	 amino	 groups	 at	 C‐2	were	 resonated	 as	 broad	
singlet	at	δ	7.07	and	7.33	ppm,	respectively.	The	SNH2	protons	
of	 compound	22	 resonated	 as	 a	 broad	 singlet	 at	 δ	5.39	 ppm,	
while	the	singlet	and	broad	singlet	at	δ	6.76	and	2.31	ppm	were	
assigned	 to	 NH	 proton	 of	 the	 pyrimidine	 thione	 20	 and	 the	
SNH2	 protons	 at	 C‐4	 of	 the	 analogue	 23,	 respectively.	 The	
singlets	 at	δ	5.35	and	5.99	ppm	were	attributed	 to	H‐5	of	 the	
pyrimidine	ring,	 in	addition	to	 two	singlets	at	δ	4.07	and	4.09	
ppm,	 assigned	 to	 the	methoxy	 group	 at	 C‐6	 of	 compound	20	
and	23,	 respectively.	Compound	24	 showed	singlet	and	broad	
singlet	 at	 δ	6.51	 and	 2.11	 ppm,	 identified	 as	H‐5	 and	 SO2NH2	
protons,	respectively.	 In	the	13C	NMR	of	compound	19‐24,	 the	
resonances	at	the	lower	field	regions	δ	189.4‐168.9	ppm	were	
assigned	to	C‐6	(C‐S)	of	the	pyrimidine	ring	 in	comparison	for	
those	of	the	starting	materials	17	and	18	at	δ	164.1	and	162.7	
ppm,	 respectively.	 C‐2,	 C‐4	 and	 C‐5	 together	 with	 the	
substituents	 carbon	 atoms	 were	 fully	 identified	 (cf	
Experimental	section).	All	the	synthesized	were	confirmed	also	
from	their	1H,	13C	HSQC	[38]	NMR	spectra.		
	
	
	
3.2.	In	vitro	anti‐HIV	activity	
	
Compounds	6‐13,	14‐16	and	19‐24	were	tested	for	their	in	
vitro	anti‐HIV‐1	(strain	IIIB)	and	HIV‐2	(strain	ROD)	activity	in	
human	T‐lymphocyte	(MT‐4)	cells	based	on	an	MTT	assay	[39].	
The	 results	 are	 summarized	 in	 Table	 1,	 in	which	 the	 data	 for	
nevirapine	 (BOE/BIRG587)	 [40]	 and	 azidothymidine	
(DDN/AZT)	[41]	were	included	for	comparison.		
	
Table	1.	In‐vitro	anti‐HIV‐1a	and	HIV‐2	b	of	new	pyrimidine	analogues	4‐16	
and	19‐27.	
Compound	 Virus	strain	 EC50	
(µg/mL)	c	
CC50	
(µg/mL)	d	
SI	e	
6 IIIB >	45.23 45.23	 <	1
ROD >	45.23 45.23	 <	1
7	 IIIB	 >	65.23	 65.23	 <	1	
ROD	 >	65.23	 65.23	 <	1	
8	 IIIB	 >	32.60	 32.60	 <	1	
ROD >	32.60 32.60	 <	1
9 IIIB >	53.60 53.60	 <	1
ROD >	53.60 53.60	 <	1
10 IIIB >	35.10 35.10	 <	1
ROD >	35.10 35.10	 <	1
11 IIIB >	12.35 12.35	 <	1
ROD >	12.35 12.35	 <	1
12	 IIIB	 >	28.05	 28.05	 <	1	
ROD	 >	28.05	 28.05	 <	1	
13	 IIIB	 >	10.04	 10.04	 <	1	
ROD >	10.04 10.04	 <	1
14	 IIIB	 >	2.12	 2.12	 <	1	
ROD >	2.12 2.12	 <	1
15 IIIB >	1.99 1.99	 <	1
ROD >	1.99 1.99	 <	1
16 IIIB >	1.80 1.80	 <	1
ROD >	1.80 1.80	 <	1
19	 IIIB	 >	11.34	 11.34	 <	1	
ROD	 >	11.34	 11.34	 <	1	
20 IIIB >	5.67 5.67	 <	1
ROD	 >	5.67	 5.67	 <	1	
21	 IIIB	 >	1.92	 1.92	 <	1	
ROD >	1.92 1.92	 <	1
22 IIIB >	3.38 3.38	 <	1
ROD >	3.38 3.38	 <	1
23 IIIB >	5.98 5.98	 <	1
ROD >	5.98 5.98	 <	1
24 IIIB >	10.18 10.18	 <	1
ROD >	10.18 10.18	 <	1
AZT IIIB 0.0022 >	25	 >	11363
ROD >	25 >	25	 >	26596
Nevirapine	 IIIB	 0.050	 0.050	 >	80	
ROD	 >	4.00	 >	4.00	 <	1	
a	Anti‐HIV‐1	activity	measured	with	strain	IIIB.	
b	Anti‐HIV‐2	activity	measured	with	strain	ROD.	
c	Compound	concentration	required	to	achieve	50	%	protection	of	MT‐4	cells	
from	the	HIV‐1	and	2‐induced	cytopathogenic	effect.	
d	Compound	concentration	 that	 reduces	 the	viability	of	mock‐infected	MT‐4	
cells	by	50%.	
e	SI:	selectivity	index	(CC50/EC50).	
	
Compounds‐induced	cytotoxicity	was	also	measured	in	MT‐
4	 cells	 parallel	 with	 the	 antiviral	 activity.	 All	 compounds	 are	
inactive	 except	 compounds	14‐16	and	21	which	showed	EC50	
values	of	>	2.12,	1.99,	1.80	and	1.92	μg/mL,	respectively,	but	no	
selectivity	was	observed	(SI	<	1).	
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Figure	3.	Docked	conformation	of	compound	15	showing	three	hydrogen	bonding:	Lys101	with	NH2 at	C‐6	and	N=N	groups	of	the	pyrimidine	ring,	in	addition	to	
Tyr186	 with	 sulfur	 atom	 of	 the	 phenylthio	 group.	 It	 exhibited	 also	 hydrophobic	 interactions	 between	 phenyl	 moieties	 and	 Tyr179,	 Tyr186	 of	 reverse	
transcriptase	(RT)	enzyme	residues.	
	
	
From	the	SAR	analysis,	we	found	that	the	alkyl‐	or	arylthio	
substituents	at	C‐4	of	the	pyrimidine	ring,	e.g.	compounds	14‐
16	or	thioalkyl	acetic	acid	moiety	at	C‐6	of	the	same	ring,	e.g.:	
compound	21	were	well	tolerated	in	the	hydrophobic	region	of	
HIV	RT	and	then	showed	higher	activity	than	those	of	the	alkyl‐	
or	 arylamino	 substituents	 at	 C‐4	 of	 the	 same	 ring;	 e.	 g.:	
compounds	6‐13,	 and	 resulted	 in	 loss	 of	 activity.	 This	means	
that	the	thio	groups	targeting	the	hydrophobic	binding	pocket	
of	HIV‐1	RT.	
	
3.3.	Molecular	modeling	analysis	
	
The	molecular	 docking	was	 performed	 using	 SYBYL‐X	 1.1	
and	 the	 docking	 results	 were	 shown	 by	 PyMOL	 [42].	 Our	
molecular	docking	analysis	of	the	new	analogues	based	on	the	
modeling	 study,	 which	 was	 performed	 to	 understand	 the	
binding	 mode	 of	 these	 analogues	 with	 the	 HIV‐RT	 binding	
pocket	(NNIBP)	(PDB	code:	3DLG,	[43]).	
Compound	15	has	been	selected	 for	 the	docking	modeling	
study,	 since	 its	 binding	 energy	 score	 ‐8.01,	 indicating	 a	
selectivity	 and	potency	profiles	 of	 substituted	 aryl‐azopyrimi‐
dine	 to	 bind	 the	 active	 site	 of	 HIV‐RT	 pocket	 (Figure	 3).	 As	
shown	 in	 figure	 3,	 the	 aromatic	 rings	 of	 compound	15	 fitted	
into	 an	 aromatic	 rich	 subpocket	 surrounded	 by	 the	 aromatic	
side	 chains	 of	 Tyr179	 and	 Tyr186.	 The	 pyrimidine	 backbone	
was	located	in	the	middle	of	the	binding	pocket,	anchoring	the	
phenylthio	 substituent	 at	 C‐4	 in	 a	 favourable	 position	 for	
hydrogen	bonding	with	the	OH	group	of	Tyr186	and	other	two	
hydrogen	bonding	of	amino	group	at	C‐6	and	azo	group	(N=N)	
at	C‐5	with	Lys103	of	the	RT	enzyme.	Overall,	the	combination	
of	 hydrophobic	 interaction	 and	 π‐stacking	 appears	 to	 govern	
the	binding	of	compound	15	with	HIV	RT.		
	
4.	Conclusion	
	
In	 conclusion,	 synthesis	of	new	2,6‐diamino‐4‐alkylamino‐
5‐p‐bromophenylazopyrimidine	 derivatives,	 6‐13,	 the	 corres‐
ponding	4‐ethyl‐	and	arylthio	analogues,	14‐16,	and	the	4‐thio	
derivatives	19‐25	has	been	described.	All	the	new	synthesized	
compounds	have	been	evaluated	for	their	activity	against	HIV‐1	
and	 2.	 Compounds	14‐16	 and	21	 exhibited	 potential	 activity	
against	HIV‐1,	whereas	 the	others	 analogues	 shown	moderate	
to	 poor	 activity.	 Compound	 15	 have	 been	 selected	 for	 the	
molecular	modeling	 study	 showing	 its	 binding	 to	 the	 reverse	
transcriptase	enzyme	pocket	 through	 three	hydrogen	bonding	
and	two	hydrophobic	interactions.		
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